GSK plc (NYSE: GSK) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 15.74 | EPS (ttm) | 3.19 | Insider Own | - | Shs Outstand | 2.00B | Perf Week | 4.34% |
| Market Cap | 100.62B | Forward P/E | 9.76 | EPS next Y | 5.14 | Insider Trans | - | Shs Float | 1.94B | Perf Month | -5.03% |
| Enterprise Value | 120.53B | PEG | 3.50 | EPS next Q | 1.84 | Inst Own | - | Short Float | 0.70% | Perf Quarter | -0.89% |
| Income | 6.49B | P/S | 2.26 | EPS this Y | 50.73% | Inst Trans | - | Short Ratio | 3.49 | Perf Half Y | -4.11% |
| Sales | 44.55B | P/B | 4.45 | EPS next Y | 6.98% | ROA | 7.81% | Short Interest | 13.55M | Perf YTD | 2.41% |
| Book/sh | 11.28 | P/C | 24.61 | EPS next 5Y | 4.50% | ROE | 28.35% | 52W High | 61.70 -18.61% | Perf Year | 24.43% |
| Cash/sh | 2.04 | P/FCF | 12.33 | EPS past 3/5Y | -25.90% 0.01% | ROIC | 16.04% | 52W Low | 39.29 27.82% | Perf 3Y | 36.62% |
| Dividend Est. | 1.81 (3.60%) | EV/EBITDA | 8.26 | Sales past 3/5Y | 6.07% 6.66% | Gross Margin | 73.29% | Volatility | 1.27% 1.49% | Perf 5Y | 26.34% |
| Dividend TTM | 1.82 (3.62%) | EV/Sales | 2.71 | EPS Y/Y TTM | 101.33% | Oper. Margin | 24.12% | ATR (14) | 1.07 | Perf 10Y | 15.05% |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 0.52 | Sales Y/Y TTM | 11.11% | Profit Margin | 14.52% | RSI (14) | 48.90 | Recom | 2.83 |
| Dividend Gr. 3/5Y | 0.34% -3.77% | Current Ratio | 0.82 | EPS Q/Q | 10.57% | SMA20 | -0.15% | Beta | 0.34 | Target Price | 60.00 |
| Payout | 55.30% | Debt/Eq | 1.11 | Sales Q/Q | 5.83% | SMA50 | -1.68% | Rel Volume | 1.30 | Prev Close | 51.06 |
| Employees | 66,841 | LT Debt/Eq | 0.92 | Earnings | Oct 28 | SMA200 | -4.14% | Avg Volume | 3.60M | Price | 50.22 |
| IPO Date | Mar 28, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.24% 0.99% | Net Debt/EBITDA | 1.38 | Volume | 4,699,925 | Change | -1.65% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-15-26 | Reiterated | Berenberg Bank | $60 | |
| Jan-06-26 | Downgrade | Barclays | Equal Weight → Underweight | |
| Oct-30-25 | Reiterated | CFRA | $53 | |
| Apr-15-25 | Initiated | BNP Paribas Exane | Neutral | $35 |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold | |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral | |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral | |
| Jul-02-24 | Reiterated | Jefferies | Buy | $53 |
| Apr-11-24 | Reiterated | Guggenheim | Buy | $36 |
| Apr-11-24 | Reiterated | Morgan Stanley | Underweight | $85 |
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 44,549 | 43,125 | 40,093 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 12,145 | 11,904 | 11,562 | — | — | — | — | — | — | |
| Gross Profit | 32,403 | 31,221 | 28,531 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 12,340 | 11,997 | 14,075 | — | — | — | — | — | — | |
| Research and Development | 12,332 | 9,934 | 8,179 | — | — | — | — | — | — | |
| Other Operating Expense | -1,505 | -1,717 | 1,139 | — | — | — | — | — | — | |
| Operating Income | 9,235 | 11,007 | 5,138 | — | — | — | — | — | — | |
| Interest Expense | 925 | 907 | 840 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -370 | -330 | 145 | — | — | — | — | — | — | |
| Net Income Before Taxes | 7,940 | 9,770 | 4,443 | — | — | — | — | — | — | |
| Income Taxes | 862 | 1,468 | 672 | — | — | — | — | — | — | |
| Consolidated Net Income | 6,485 | 7,546 | 3,290 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 7,078 | 8,302 | 3,771 | — | — | — | — | — | — | |
| Net Income | 6,485 | 7,546 | 3,290 | — | — | — | — | — | — | |
| EPS (Recurring) | 3.23 | 3.72 | 1.61 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.23 | 3.72 | 1.61 | — | — | — | — | — | — | |
| EPS (Diluted) | 3.19 | 3.67 | 1.58 | — | — | — | — | — | — | |
| EBITDA | 14,597 | 13,732 | 8,521 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 15.74 | 13.36 | 21.34 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.26 | 2.30 | 1.72 | — | — | — | — | — | — | |
| Gross Margin | 72.74 | 72.40 | 71.16 | — | — | — | — | — | — | |
| Operating Margin | 20.73 | 25.52 | 12.82 | — | — | — | — | — | — | |
| Net Margin | 14.56 | 17.50 | 8.21 | — | — | — | — | — | — | |
| Shares Outstanding | 2,007 | 2,026 | 2,039 | — | — | — | — | — | — | |
| Market Capitalization | 100,792 | 99,355 | 68,959 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |